{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023058","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.161879+00:00","generated_at":"2026-06-05T06:56:30.753380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024","bullets":["Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.","Rezatapopt Phase 1 data: confirmed ORR 38% at RP2D (2000 mg daily), median DOR 7 months in TP53 Y220C/KRAS WT patients.","Registrational Phase 2 portion of PYNNACLE trial on track to initiate Q1 2024; FDA alignment on RP2D and key Phase 2 design elements.","Phase 1 analysis in ovarian cancer subgroup selected as late-breaking oral presentation at 2024 SGO Annual Meeting on March 18.","Net loss $69.0M vs $73.3M in 2022; R&D expenses $55.9M, G&A $24.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023058","json":"https://secwatch.observer/filing/0000950170-24-023058.json","markdown":"https://secwatch.observer/filing/0000950170-24-023058.md","text":"https://secwatch.observer/filing/0000950170-24-023058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/0000950170-24-023058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/pmvp-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:56:30.753380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f281ee22fe2cdcdc3ce0233444cdf19da57b99f8","claim":"PMV Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3.","evidence_excerpt":"Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/0000950170-24-023058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}